The global autoinjectors market size is calculated at USD 75.83 billion in 2025 and is projected to surpass around USD 362.89 billion by 2034, expanding at a CAGR of 19% from 2025 to 2034. The North America autoinjectors market size surpassed USD 28.67 billion in 2024 and is expanding at a CAGR of 19.02% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Autoinjectors Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Autoinjectors Market, by Therapy
8.1.1. Rheumatoid Arthritis
8.1.1.1. Market Revenue and Forecast
8.1.2. Multiple Sclerosis
8.1.2.1. Market Revenue and Forecast
8.1.3. Diabetes
8.1.3.1. Market Revenue and Forecast
8.1.4. Anaphylaxis
8.1.4.1. Market Revenue and Forecast
8.1.5. Other Therapies
8.1.5.1. Market Revenue and Forecast
9.1. Autoinjectors Market, by Type
9.1.1. Disposable
9.1.1.1. Market Revenue and Forecast
9.1.2. Reusable
9.1.2.1. Market Revenue and Forecast
10.1. Autoinjectors Market, by Route of Administration
10.1.1. Subcutaneous
10.1.1.1. Market Revenue and Forecast
10.1.2. Intramuscular
10.1.2.1. Market Revenue and Forecast
11.1. Autoinjectors Market, by Type of Molecule
11.1.1. Monoclonal Antibody
11.1.1.1. Market Revenue and Forecast
11.1.2. Peptide
11.1.2.1. Market Revenue and Forecast
11.1.3. Protein
11.1.3.1. Market Revenue and Forecast
11.1.4. Small Molecule
11.1.4.1. Market Revenue and Forecast
12.1. Autoinjectors Market, by End-User
12.1.1. Home Care Settings
12.1.1.1. Market Revenue and Forecast
12.1.2. Hospitals & Clinics
12.1.2.1. Market Revenue and Forecast
12.1.3. Ambulatory Care Settings
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Therapy
13.1.2. Market Revenue and Forecast, by Type
13.1.3. Market Revenue and Forecast, by Route of Administration
13.1.4. Market Revenue and Forecast, by Type of Molecule
13.1.5. Market Revenue and Forecast, by End-User
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Therapy
13.1.6.2. Market Revenue and Forecast, by Type
13.1.6.3. Market Revenue and Forecast, by Route of Administration
13.1.6.4. Market Revenue and Forecast, by Type of Molecule
13.1.6.5. Market Revenue and Forecast, by End-User
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Therapy
13.1.7.2. Market Revenue and Forecast, by Type
13.1.7.3. Market Revenue and Forecast, by Route of Administration
13.1.7.4. Market Revenue and Forecast, by Type of Molecule
13.1.7.5. Market Revenue and Forecast, by End-User
13.2. Europe
13.2.1. Market Revenue and Forecast, by Therapy
13.2.2. Market Revenue and Forecast, by Type
13.2.3. Market Revenue and Forecast, by Route of Administration
13.2.4. Market Revenue and Forecast, by Type of Molecule
13.2.5. Market Revenue and Forecast, by End-User
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Therapy
13.2.6.2. Market Revenue and Forecast, by Type
13.2.6.3. Market Revenue and Forecast, by Route of Administration
13.2.7. Market Revenue and Forecast, by Type of Molecule
13.2.8. Market Revenue and Forecast, by End-User
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Therapy
13.2.9.2. Market Revenue and Forecast, by Type
13.2.9.3. Market Revenue and Forecast, by Route of Administration
13.2.10. Market Revenue and Forecast, by Type of Molecule
13.2.11. Market Revenue and Forecast, by End-User
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Therapy
13.2.12.2. Market Revenue and Forecast, by Type
13.2.12.3. Market Revenue and Forecast, by Route of Administration
13.2.12.4. Market Revenue and Forecast, by Type of Molecule
13.2.13. Market Revenue and Forecast, by End-User
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Therapy
13.2.14.2. Market Revenue and Forecast, by Type
13.2.14.3. Market Revenue and Forecast, by Route of Administration
13.2.14.4. Market Revenue and Forecast, by Type of Molecule
13.2.15. Market Revenue and Forecast, by End-User
13.3. APAC
13.3.1. Market Revenue and Forecast, by Therapy
13.3.2. Market Revenue and Forecast, by Type
13.3.3. Market Revenue and Forecast, by Route of Administration
13.3.4. Market Revenue and Forecast, by Type of Molecule
13.3.5. Market Revenue and Forecast, by End-User
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Therapy
13.3.6.2. Market Revenue and Forecast, by Type
13.3.6.3. Market Revenue and Forecast, by Route of Administration
13.3.6.4. Market Revenue and Forecast, by Type of Molecule
13.3.7. Market Revenue and Forecast, by End-User
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Therapy
13.3.8.2. Market Revenue and Forecast, by Type
13.3.8.3. Market Revenue and Forecast, by Route of Administration
13.3.8.4. Market Revenue and Forecast, by Type of Molecule
13.3.9. Market Revenue and Forecast, by End-User
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Therapy
13.3.10.2. Market Revenue and Forecast, by Type
13.3.10.3. Market Revenue and Forecast, by Route of Administration
13.3.10.4. Market Revenue and Forecast, by Type of Molecule
13.3.10.5. Market Revenue and Forecast, by End-User
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Therapy
13.3.11.2. Market Revenue and Forecast, by Type
13.3.11.3. Market Revenue and Forecast, by Route of Administration
13.3.11.4. Market Revenue and Forecast, by Type of Molecule
13.3.11.5. Market Revenue and Forecast, by End-User
13.4. MEA
13.4.1. Market Revenue and Forecast, by Therapy
13.4.2. Market Revenue and Forecast, by Type
13.4.3. Market Revenue and Forecast, by Route of Administration
13.4.4. Market Revenue and Forecast, by Type of Molecule
13.4.5. Market Revenue and Forecast, by End-User
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Therapy
13.4.6.2. Market Revenue and Forecast, by Type
13.4.6.3. Market Revenue and Forecast, by Route of Administration
13.4.6.4. Market Revenue and Forecast, by Type of Molecule
13.4.7. Market Revenue and Forecast, by End-User
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Therapy
13.4.8.2. Market Revenue and Forecast, by Type
13.4.8.3. Market Revenue and Forecast, by Route of Administration
13.4.8.4. Market Revenue and Forecast, by Type of Molecule
13.4.9. Market Revenue and Forecast, by End-User
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Therapy
13.4.10.2. Market Revenue and Forecast, by Type
13.4.10.3. Market Revenue and Forecast, by Route of Administration
13.4.10.4. Market Revenue and Forecast, by Type of Molecule
13.4.10.5. Market Revenue and Forecast, by End-User
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Therapy
13.4.11.2. Market Revenue and Forecast, by Type
13.4.11.3. Market Revenue and Forecast, by Route of Administration
13.4.11.4. Market Revenue and Forecast, by Type of Molecule
13.4.11.5. Market Revenue and Forecast, by End-User
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Therapy
13.5.2. Market Revenue and Forecast, by Type
13.5.3. Market Revenue and Forecast, by Route of Administration
13.5.4. Market Revenue and Forecast, by Type of Molecule
13.5.5. Market Revenue and Forecast, by End-User
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Therapy
13.5.6.2. Market Revenue and Forecast, by Type
13.5.6.3. Market Revenue and Forecast, by Route of Administration
13.5.6.4. Market Revenue and Forecast, by Type of Molecule
13.5.7. Market Revenue and Forecast, by End-User
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Therapy
13.5.8.2. Market Revenue and Forecast, by Type
13.5.8.3. Market Revenue and Forecast, by Route of Administration
13.5.8.4. Market Revenue and Forecast, by Type of Molecule
13.5.8.5. Market Revenue and Forecast, by End-User
14.1. AbbVie Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Mylan
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Eli Lilly and Company
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Ypsomed
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Amgen
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Becton
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Dickinson and Company
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Antares Pharma
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. GlaxoSmithKline plc
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Johnson & Johnson
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample